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Abstract
The blood-brain barrier (BBB) is formed by brain capillary endothelial cells (BECs) sup-
ported by pericytes and astrocytes. The BBB maintains homeostasis and protects the brain
against toxic substances circulating in the blood, meaning that only a few drugs can pass
the BBB. Thus, for drug screening, understanding cell interactions, and pathology, in vitro
BBB models have been developed using BECs from various animal sources. When compar-
ing models of different species, differences exist especially in regards to the transendothelial
electrical resistance (TEER). Thus, we compared primary mice, rat, and porcine BECs
(mBECs, rBECs, and pBECs) cultured in mono- and co-culture with astrocytes, to identify
species-dependent differences that could explain the variations in TEER and aid to the
selection of models for future BBB studies. The BBB models based on primary mBECs,
rBECs, and pBECs were evaluated and compared in regards to major BBB characteristics.
The barrier integrity was evaluated by the expression of tight junction proteins and measure-
ments of TEER and apparent permeability (Papp). Additionally, the cell size, the functional-
ity of the P-glycoprotein (P-gp) efflux transporter, and the expression of the transferrin
receptor were evaluated and compared. Expression and organization of tight junction pro-
teins were in all three species influenced by co-culturing, supporting the findings, that TEER
increases after co-culturing with astrocytes. All models had functional polarised P-gp efflux
transporters and expressed the transferrin receptor. The most interesting discovery was
that even though the pBECs had higher TEER than rBECs and mBECs, the Papp did not
show the same variation between species, which could be explained by a significantly larger
cell size of pBECs. In conclusion, our results imply that the choice of species for a given
BBB study should be defined from its purpose, instead of aiming to reach the highest TEER,
as the models studied here revealed similar BBB properties.
Introduction
The blood-brain barrier (BBB) is a protective barrier formed by non-fenestrated brain capillary
endothelial cells (BECs), which are supported by pericytes embedded in the basement mem-
brane and astrocytic endfeet [1]. Pericytes cover approximately 30% of brain capillaries, while
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the astrocytic endfeet cover approximately 99% [2]. The BBB protects the vulnerable neurons
against potentially harmful substances circulating in the blood by controlling the entrance of
blood-borne substances into the brain [3]. However, the restrictive properties of the BBB
become a major hurdle in the treatment of diseases affecting the central nervous system
(CNS), as only a few drugs can pass the BBB and enter the CNS [4]. This has created a great
interest in and a need for the development of in vitro BBB models that mimic the in vivo BBB.
The BECs are highly sophisticated cells characterized by high transendothelial electrical
resistance (TEER), low permeability, low vesicular transport, and high expression of tight junc-
tion proteins, various transporters, and receptors important for maintaining the restrictive
function of the BECs. The tight junction proteins claudin (CLDs), occludin (OCLN), and junc-
tional adhesion molecules (JAMs) form the paracellular barrier and these are closely associated
with the scaffolding and regulatory proteins zonula occludens (ZO)-1-3 [1, 5, 6]. The BECs
also express efflux transporters of the ABC family such as breast cancer resistance proteins
(BCRP) and P-glycoprotein (P-gp), which furthermore hinder brain delivery of small lipo-
philic drugs [7–9]. To ensure the supply of important nutrients to the brain, BECs also express
several specific solute carriers like the glucose transporter 1 (GLUT1) and receptors such as
the transferrin receptor 1 (TfR) [1]. The presence of pericytes and astrocytes supports the char-
acteristics of the BECs through cell-cell interactions and communication through solute fac-
tors [10–14]. In vitro BBB models, should, therefore, mimic as many of these characteristics as
possible and this have led to the creation of many different models, some more complex than
others.
The simplest in vitro BBB models are created from immortalized cell lines. These models
are easy and cheap to construct and highly suitable for high throughput screening of potential
drug candidates. Unfortunately, these models do not mimic the complexity of the BBB in vivo
[15, 16], why primary cells have become the preferred cell type, as these maintain many of the
in vivo characteristics, like the expression of important tight junction proteins, solute carriers,
receptors, efflux transporters, and they display high TEER and low permeability [15, 16]. The
Transwell system, which is a widely used system in the construction of in vitro BBB models,
allows for the formation of a polarized BEC layer with defined luminal and abluminal com-
partments, and it further provides co-culturing possibilities with pericytes and/or astrocytes.
Co-culturing the BECs with pericytes and/or astrocytes in so-called co- and triple-culture
models increases and maintains many of the in vivo characteristics of the BECs [13, 17–19].
Primary BECs, pericytes, and astrocytes have been isolated from several different species and
used in the search for the optimal in vitro BBB model. The most extensively studied models
utilize primary cells isolated from mice, rats, porcine, or bovine brains [15, 20–33].
Primary BECs isolated from different species all display several of the important in vivo
characteristics, however when comparing in vitro BBB models constructed from primary cells
of different species, one obvious difference has become evident. The TEER is highly variable
across species, with the primary mBECs and rBECs exhibiting lower TEER values than pBECs
and bovine BECs [20, 22, 34, 35]. This has created an ongoing discussion within the BBB com-
munity regarding the most favorable model, and whether the mice and rat models should be
considered leaky and therefore unfavorable due to the lower TEER values obtained using these
models, compared to those obtained with the porcine and bovine cells. Two methods are nor-
mally used to evaluate the BBB integrity in vitro, with the first being TEER and the second
being the apparent permeability (Papp) of small hydrophilic molecules. Of the two, TEER is
the most widely used, due to its easy and convenient use [36]. To our knowledge, no study to
this date has investigated and compared the relationship between the Papp and TEER in differ-
ent in vitro models constructed from BECs of different origin or have attempted to explain the
significant differences observed in TEER among species.
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The present study, therefore, compares three species-specific in vitro BBB models, to inves-
tigate the underlying reason for the major variation observed in TEER between species, but
also to add to the selection of in vitro BBB models for future studies. The three species-specific
in vitro BBB models studied are the mice, rat, and porcine models, as these are all well-charac-
terized and highly used in our laboratory [22, 28, 31, 37–42]. We have previously characterized
mice, rat, and porcine mono-, co-, and triple-cultures, showing that co-culturing the BECs
with both astrocytes and pericytes do not further increase TEER significantly or cause signifi-
cantly lower apparent permeability to small molecules compared to co-cultures with only
astrocytes [22, 28, 31]. Thus, for the objective of the present study, we constructed the two
most commonly used in vitro BBB models, namely the mono-culture and the non-contact co-
culture model using primary mice, rat, and porcine BECs (mBECs, rBECs, pBECs) and pri-
mary astrocytes of the same origin. The primary BECs of the present study were all derived
from the same isolation protocol with only minor modifications, making the models highly
comparable. The models were compared with regards to major BECs characteristics, like the
expression of tight junction proteins, efflux transport, expression of the TfR; a widely studied
target for drug delivery to the brain [43], and most importantly, the barrier integrity.
Materials and methods
All materials were obtained from Sigma-Aldrich unless otherwise stated.
Isolation of mBECs, rBECs, and pBECs
Isolation of mBECs, rBECs, and pBECs has previously been described in [22, 28, 31]. The
method was originally adapted from the isolation of rBECs and has later been slightly modified
for application in mBECs and pBECs. The modifications were adopted in the first step of the
purification procedure.
Handling of rats and mice took place in the animal facility at Aalborg University and was
approved by the Danish National Council of Animal Welfare. The porcine brains were
obtained from approximately six-month-old domestic pigs, donated by the local abattoir
(Danish Crown, Sæby, Denmark). A single batch of mBECs requires 12–15, six to teen week
old C57BL/6 mice brains, and 9–12, two-to-three weeks old Sprague-Dawley rat brains are
needed for one batch of rBECs. Mice and rats were deeply anesthetized with isoflurane and
sacrificed by decapitation. The forebrains were dissected under sterile conditions, and the
meninges and visible white matter were removed. The porcine brains were transported on ice
from the local abattoir to the laboratory facility. The meninges were removed and for a single
batch of cells, 12 grams of grey matter was carefully dissected. From here on the protocols for
isolation of BECs are identical across species.
The collected brain tissue was minced and digested in Dulbecco’s modified Eagle medium
with nutrient mixture F12 (DMEM-F12) (Life technologies) with collagenase type II (1mg/ml;
Life Technologies) and DNase I (20μg/ml) at 37˚C for 75 minutes in an incubating mini shaker
(VWR). The digested brain material was pelleted by centrifugation and resuspended in 20%
bovine serum albumin (BSA) (Europa Bioproducts) in DMEM and centrifuged at 1000 x g for
20 min. The pellet was further digested in DMEM-F12 containing collagenase-dispase
(0.75mg/ml) and DNase I (7.5μg/ml) for 50 minutes at 37˚C in the incubating mini shaker.
The digested material was again pelleted by centrifugation and loaded on a 33% Percoll gradi-
ent to obtain microvessels. The microvessels were collected and washed twice in DMEM-F12,
resuspended in BECs media consisting of DMEM-F12 supplemented with 10% Bovine plate-
let-poor plasma-derived serum (First Link), 10μg/ml Insulin-transferrin-sodium selenite,
10μg/mL gentamicin (Lonza), and 1ng/mL freshly added basic fibroblast growth factor (bFGF)
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(PeproTech), and seeded in collagen type IV (0.15mg/ml)/fibronectin (0.05mg/ml)-coated
Petri dishes or culture flasks. The BECs medium was supplemented with 4μg/mL puromycin
for the first 3–4 days of culture to obtain pure cultures of BECs [44]. The BECs medium for
culturing pBECs was additionally supplemented with chloramphenicol for the first three days
of culture, due to the high occurrence of methicillin-resistant staphylococcus aureus (MRSA)
(CC398) in Danish domestic pigs. BECs were maintained at 37˚C in 5% CO2 in a humidified
atmosphere. The growth of the BECs was analyzed in a Primo Vert phase-contrast microscope
(Carl-Zeiss, Germany) equipped with an AxioCam ERc5s camera, and analyzed for brightness
contract in ImageJ [45].
Isolation of astrocytes
Astrocytes were isolated from mice, rats, and porcine brains according to previously published
protocols [22, 28, 31]. Mouse and rat astrocytes were isolated from one to two, two-day-old
C57BL/6 mice and Sprague-Dawley rat brains, respectively. The porcine astrocytes were iso-
lated from the brains of six-month-old domestic pigs obtained from the local abattoir.
The mice and rat pups were decapitated and their brains were collected, while 1–2 grams of
porcine brain tissue were collected. The brains/brain tissue was suspended in astrocyte media
consisting of DMEM (Life Technologies), supplemented with 10% fetal calf serum (FCS) and
10μg/mL gentamycin. The tissue was mechanically dissociated with a Hypodermic needle 21G
x 3 1/8“(Sterica B. Braun Medical A/S), filtered through a 40μm Corning cell strainer. The fil-
tered cell suspension was seeded onto Poly-L-Lysine (500μg/ml) coated culture flasks, and
maintained at 37˚C and 5% CO2 in a humidified atmosphere. The cells were cultured for two
to three weeks, with medium changes every third day, after which they were reseeded in poly-
L-lysine coated 12 well culture plates and cultured for another one to two weeks prior to co-
culturing with BECs. The medium for porcine astrocytes was also supplemented with chloram-
phenicol for the first three days. The astrocyte cultures also contain few microglia cells [22,
28], however, throughout the manuscript, the culture will be referred to as astrocytes.
In vitro BBB model construction
The BECs were cultured either as a mono-culture or in a non-contact co-culture with astro-
cytes, referred to as a “co-culture” from here on. BECs were seeded at a density of approxi-
mately 100,000 cells/cm2 on collagen/fibronectin double-coated hanging culture inserts (1μm
pore size, 1.12cm2) (In Vitro A/S) in 12 well plates and left to adhere and proliferate for 24
hours to obtain a confluent monolayer. To construct the co-culture of BECs with astrocytes,
the hanging culture inserts with BECs were transferred to a 12 well plate containing astrocytes.
To induce BBB characteristics in both models, the BECs media was supplemented with 250μM
8-(4-Chlorophenylthio)adenosine 30,50-cyclic monophosphate sodium salt (CTP-cAMP),
17.5μM RO-1724 (RO), and 550nM hydrocortisone (HC) in the upper chamber and 550nM
HC in the lower chamber. In the co-culture model, the media composition of the lower cham-
ber was a combination of BECs media and astrocyte conditioned media (1:1). Astrocyte condi-
tioned medium is medium, which has been in contact with the astrocyte culture for at least 24
hours.
Transendothelial electrical resistance measurements
The barrier integrity of the in vitro BBB models was assessed through measurements of TEER
using Millicell ERS-2 epithelial volt-ohm Meter and STX01 Chopstick Electrodes (Merck
Millipore). The TEER value for each hanging culture insert was obtained from an average of
three individual measurements subtracted from the TEER value of a double-coated cell-free
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hanging culture insert and multiplied by the area of the hanging culture insert (1.12cm2).
TEER was measured once a day after seeding of the BECs on the hanging culture inserts.
Apparent permeability
The Papp of radiolabeled [3H]-D-Mannitol (PerkinElmer) was measured to further assess the
barrier integrity of the different in vitro BBB models. 1μCi [3H]-D-Mannitol (Specific activity
15.9 Ci/mol) was added to the medium inside the hanging culture insert (donor compart-
ment), and samples of 100 μl medium were collected from the lower chamber (receiver com-
partment) at 0, 15, 30, 60, 90, and 120 min, and replaced with 100 μl fresh medium. The cells
were incubated at 37˚C under mild agitation. The samples were mixed with Ultima Gold™ liq-
uid scintillation cocktail (PerkinElmer) and the radioactivity was counted in a Hidex 300SL
liquid scintillation counter. The total amount of mannitol transported across the BECs was
plotted against time and the slope at steady-state was calculated. Subsequently, Papp (cm/s)
was calculated by dividing the slope with the area of the culture insert (1.12cm2) multiplied by
the initial concentration. For each filter insert the calculated Papp data were plotted against
TEER. Cells from at least two different batches were used, resulting in 12–16 filter inserts for
each culture condition and each species.
Gene expression analysis
RNA was isolated from both mono- and co-cultured BECs from each species to evaluate the
gene expression levels of tight junction proteins (Cld1, Cld3, Cld5, Ocln, Zo1, and Zo2), recep-
tors (TfR), and efflux transporters (P-gp and Bcrp). RNA was isolated on the day of the
expected highest TEER, thus RNA from mBECs and rBECs was isolated on day two or three,
and RNA from pBECs was isolated on day three to four (Fig 1A). Each RNA sample consisted
of a pool of cells from three hanging culture inserts and cells from at least two different batches
were used, resulting in a total of six RNA samples. RNA was extracted using the GeneJET
RNA Purification Kit (Life Technologies), according to the manufacture’s guidelines. Genomic
DNA was removed using DNase I enzyme (Life Technologies) before cDNA synthesis, which
was carried out using the Maxima H Minus First-Strand Synthesis Kit (Life Technologies).
2.5ng cDNA and 10pmol of each primer (TAG Copenhagen) were added to the Maxima™
SYBR Green qPCR Master Mix in a final reaction volume of 20μL. For normalization pur-
poses, β-actin (Actb) and hypoxanthine phosphoribosyltransferase 1 (Hprt1) were used as
housekeeping genes, while non-reverse transcribed RNA and water served as negative con-
trols. A list of primer sequences used in the qPCR can be found in Tables 1–3. qPCR was per-
formed using the Stratagene Mx3000P™ QPCR system (Agilent Technologies) running the
following program: 95˚C for 10 min, 40 cycles of 95˚C for 30 sec, 60˚C for 30 sec, and 72˚C for
30 sec. The relative expression of mRNA was calculated according to the Pfaffl-method with
the mono-cultured BECs of each species serving as the calibrator sample (control) [46].
Immunocytochemistry
Immunocytochemical stains were performed on mice, rats, and porcine astrocytes using the
astrocyte marker glial-fibrillary acid protein (GFAP). Additionally, both mono- and co-cul-
tured BECs were immunolabeled to evaluate the expression and localization of tight junction
proteins (CLD5, OCLN, ZO-1, ZO-2), receptors (TfR), and efflux transporters (P-gp). The
cells were washed twice in 0.1M phosphate-buffered saline (PBS), fixated for 5–10 min in 4%
paraformaldehyde, and washed twice in 0.1M PBS. To block unspecific binding of the antibod-
ies, the cells were incubated for 30 min in a blocking buffer consisting of 3% BSA and 0.3% Tri-
ton X-100 in 0.1M PBS, before the addition of primary antibodies (Table 4). All incubations
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Fig 1. Overview of the construction of the different in vitro blood-brain barrier (BBB) models. (A) Mouse brain capillary
endothelial cells (mBECs) are isolated on day -4, while both rat BECs (rBECs) and porcine BECs (pBECs) are isolated on day -3. The
BECs are grown in a medium containing puromycin until day 0, to secure a pure BECs culture. On day 0, the cells are re-seeded on
collagen IV/fibronectin-coated hanging culture inserts. 24 hours later, the BBB properties are induced by the addition of RO 20–
1724 (RO), 8-(4-Chlorophenylthio)adenosine 30,50-cyclic monophosphate sodium salt (pCPT-cAMP), and hydrocortisone (HC),
and the BECs are subsequently cultured as mono-culture or in co-culture with astrocytes isolated from mice, rat, or porcine brains.
(B) Phase-contrast images of the isolated microvessels from day -4 or -3 to day 0 for mBECs, rBECs, and pBECs. The isolated
microvessels (arrowheads and boxes) are recognized as small pearls on a string. After 24 hours the BECs start to proliferate from the
microvessels, which is highlighted in the box and by the arrowheads. The cells reach a confluence level of 80–90% on day 0. Scale
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were performed at room temperature under mild agitation. BECs were incubated with primary
antibodies diluted 1:200–1:250 in blocking buffer for one hour and washed twice with washing
buffer (blocking buffer diluted 1:50 in 0.1M PBS). Secondary goat anti-rabbit Alexa Fluor 488
(Invitrogen, Cat. No. A11034), donkey anti-mouse Alexa Fluor 488 (Invitrogen, Cat. No.
A21202) or donkey anti-rat Alexa Fluor 488 (Invitrogen. Cat. No A21208) antibodies were
diluted 1:200–1:250 in incubation buffer and added to the cells for one hour. Secondary anti-
bodies were aspirated, and the cells washed twice in 0.1M PBS. The nuclei were stained with
DAPI (1:500 in 0.1M PBS) and mounted on glass slides using fluorescent mounting media
(DAKO) and examined in a fluorescence Observer Z1 microscope with ApoTome 2 under a
Plan-Apochromat 40x/1.3 Oil DIC objective (Carl Zeiss). Captured images were processed
using ImageJ [45].
The functionality of the P-glycoprotein efflux transporter
To assess the functionality of the efflux transporter P-gp, the Papp of the radiolabeled P-gp
substrate [3H]-digoxin (PerkinElmer) was measured in the luminal to abluminal (L-A) and
abluminal to luminal (A-L) direction in the presence or absence of the P-gp inhibitor zosuqui-
dar (ZSQ) (Selleckchem) for both mono- and co-cultured BECs from the three species. 0.4 μM
ZSQ [47] or equal amounts of water were added to both the luminal (L) and abluminal (A)
chamber 15 min before the addition of 1μCi/ml [3H]-digoxin to either the upper (L-A) or
lower chamber (A-L). The cells were incubated at 37˚C for two hours under mild agitation.
Cell culture medium from the opposite chamber from where the [3H]-digoxin was added, was
collected at 0, 15, 30, 60, 90, and 120 min, and replaced with equal amounts of fresh medium.
Samples sizes of 50μl were obtained from the upper chamber, while 100μl samples were col-
lected from the lower chamber. The samples were mixed with Ultima Gold™ liquid scintillation
cocktail, and the radioactivity was counted in a Hidex 300SL liquid scintillation counter. The
Papp for luminal to abluminal (L-A) and abluminal-luminal (A-L) was calculated as described
for mannitol. The Papp was used to calculate the efflux ratio (ER), which refers to the ratio of
Papp(A-L)/Papp(L-A). Cells from at least two different batches were used (n = 6).
bar = 20μM. (C) Immunofluorescent images of the primary astrocyte cultures isolated from mouse, rat, and porcine brains used for
the creation of co-cultures. The astrocytes express the glial fibrillary acidic protein (GFAP; red), though at varying intensity,
confirming the presence of astrocytes in these cultures. The nuclei are stained with DAPI (blue). Scale bar = 20μM.
https://doi.org/10.1371/journal.pone.0236770.g001
Table 1. Overview of the primers used for mBECs.
Mus Musculus
Gene NCBI FW REV
Actb NM_007393.3 CTGTCGAGTCGCGTCCACC TCGTCATCCATGGCGAACTGG
Hprt1 NM_013556.2 GTTGGATACAGGCCAGACTTTGTTG GATTCAACTTGCGCTCATCTTAGGC
Cld1 NM 016674.4 CACCGGGCAGATACAGTGCAA ATGCACTTCATGCCAATGGTGGA
Cld3 NM_009902.4 CCTCTATTCTGCGCCGCGAT CGACTGCTGGTAGTGGTGACG
Cld5 NM_013805.4 AGGATGGGTGGGCTTGATCCT GTACTCTGCACCACGCACGA
Ocln NM_008756.2 GATTCCGGCCGCCAAGGTT TGCCCAGGATAGCGCTGACT
Zo1 (Tjp1) NM_001163574 GAGACGCCCGAGGGTGTAGG TGGGACAAAAGTCCGGGAAGC
P-gp (Abcb1) NM_011076.2 AGGTAGAGACACGTGAGGTCGT AACATTGTAAGCACACTGACTGCTG
Bcrp (Abcg2) NM_011920.3 GGCCATAGCCACAGGCCAAA GACAGCCAAGGCCCAATGGT
TfR NM_011638.4 CTATAAGCTTTGGGTGGGAGGCA AGAATGCTGATCTGGCTTGATCCAT
https://doi.org/10.1371/journal.pone.0236770.t001
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Table 3. Overview of the primers used for pBECs.
Sus Scrofa
Gene NCBI FW REV
Actb XM_003124280.2 CAGAGCGCAAGTACTCCGTGTGGAT GCAACTAACAGTCCGCCTAGAAGCA
Hprt1 NM_001032376.2 AATGCAAACCTTGCTTTCCTTGGTC GGCATAGCCTACCACAAACTTGTCT
Cld1 NM_001244539.1 ATCCTGCTGGGACTAATAGCCATCT CCATACCATGCTGTGGCAACTAAGA
Cld5 NM_001161636.1 GTCTTGTCTCCAGCCATGGGTTC GTCACGATGTTGTGGTCCAGGAAG
Ocln NM_001163647.2 GCCCATCCTGAAGATCAGGTGAC CTCCACCATATATGTCGTTGCTGGG
Zo1 (Tjp1) XM_021098896.1 AAGCCTCCAGAGGGAGCATCTAA ATATCTTCAGGTGGCTTCACTTGGG
Zo2 (Tjp2) NM_001206404.1 ACAGAGGTTGAACCCATCATCCAAC AATTGTGTCCTTCAAGCTGCCAAAC
P-gp (Abcb1) XM_003130205.2 CGATGGATCTTGAAGAAGGCCGAAT CCAGTTTGAATAGCGAAACATGGCA
Bcrp (Abcg2) NM_214010.1 GCTATCGAGTGAAAGTGAAGAGTGGCT AACAACGAAGATTTGCCTCCACCTG
TfR NM_214001.1 TTGATGATGCTGCTTTCCCTTTCCT CCATTCTGTTCAACTGAGGAACCCT
https://doi.org/10.1371/journal.pone.0236770.t003
Table 4. Overview of primary antibodies used for immunolabeling.
Target: Mouse astrocytes Rat astrocytes Porcine Astrocytes
GFAP Rabbit anti-bovine-GFAP, polyclonal, Agilent (Cat. No. Z0334), AB_10013382
mBECs rBECs pBECs
CLD5 Rabbit anti-human CLD5, polyclonal, Sigma Aldrich, (Cat.No. SAB4502981), AB_10753223
OCLN Rabbit anti-human OCLN, polyclonal, Millipore, (Cat. No. ABT146),
ZO-1 Rabbit anti-human ZO-1, polyclonal, ThermoFischer Scientific (Cat.No. 61–7300) AB_138452
ZO-2 Rabbit anti-ZO-2, polyclonal, Invitrogen, (Cat No 71–1400), AB_2533976
P-gp Rabbit anti-human P-gp, polyclonal, Abcam (Cat. No. ab129450), AB_11157199
TfR Rat anti-mouse TfR (RI7217), monoclonal, produced in-
house via the hybridoma technique Clone: R17217 (RI7
217.1.4)
Mouse anti-rat CD71 (OX26), monoclonal,
Bio-Rad (Cat. No MCA155G) AB_2201358
Rabbit anti-porcine TfR, polyclonal,
MyBioSource (Cat. No. MBS2052130)
Rabbit anti-human CD71, polyclonal,
Proteintech (Cat. No 10084-2-AP) AB_2240403
Rabbit anti-human Transferrin Receptor,
polyclonal, Abcam (Cat. No Ab84036) AB_
10673794
https://doi.org/10.1371/journal.pone.0236770.t004
Table 2. Overview of the primers used for rBECs.
Rattus Norveigus
Gene NCBI FW REV
Actb NM_031144.3 CCTCTGAACCCTAAGGCCAACCGTGAA AGTGGTACGACCAGAGGCATACAGGG
Hprt1 NM_012583,2 TGCAGACTTTGCTTTCCTTGGTCA TGGCCTGTATCCAACACTTCGAG
Cld1 NM_031699.2 ATCGTGACTGCTCAGGCCATC TACCATCAAGGCTCTGGTTGCC
Cld3 NM_031700.2 ATTACCTGGCCTAGGAACTGTCCAA TAGTTTGCCTGTCTCTGCCCACTAT
Cld5 NM_031701.2 CTACAGGCTCTTGTGAGGACTTGAC AGTAGGAACTGTTAGCGGCAGTTTG
Ocln NM_031329.2 CTGACTATGCGGAAAGAGTCGACAG AGAGGAATCTCCTGGGCTACTTCAG
Zo1 (Tjp1) NM_001106266.1 GCCTGCCAAGCCAGTCCATT ACTGTGAGGGCAACGGAGGA
Zo2 (Tjp2) NM_053773.1 CTGCGCGCTGACACTGCT CTGTGCGCTGCAGAGTGCTT
P-gp (Abcb1) NM_012623.2 AATCAACAGTACACAGACCGTCAGC CCAAAGTGAAACCTGGATGTAGGCA
Bcrp (Abcg2) NM_181381.2 GAGTTAGGCCTGGACAAAGTAGCAG AATCAACAGTACACAGACCGTCAGC
TfR NM_022712.1 TGGATCAAGCCAGATCAGCATTCTC TTTCTTCCTCATCTGCAGCCAGTTT
https://doi.org/10.1371/journal.pone.0236770.t002
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Cell size analysis
The size of the BECs from each species was analyzed using ImageJ. Two hanging culture
inserts from two different batches (a total of four hanging culture inserts per culturing condi-
tion) were immunolabeled for a tight junction marker, as previously described, and examined
in a fluorescence Observer Z1 microscope with ApoTome 2 under a Plan-Apochromat 40x/1.3
Oil DIC objective. Two images were acquired per hanging culture insert under blinded condi-
tions, resulting in a total of four images per culture condition included in the analysis (a total
of eight images per species). Captured images were corrected for brightness and contrast and
all uncut cells on each image were marked using the free-hand tools, and the area measured
using Image J. The average cell area per image, taken from all cells marked by the tight junc-
tion staining of each image, was calculated and used in the analysis, resulting in a sample size
of four per culturing condition (n = 4).
Statistical analysis
Results are shown as mean ± standard deviation (SD). All experiments were performed at least
twice using cells from two different batches of BECs. No blinding was used, except when ana-
lyzing images to determine the size differences between mBECs, rBECs, and pBECs. Statistical
analysis was performed on data from the gene expression analysis and in the analysis of cell
size. All graphs and statistical analyses were made using GraphPad Prism (version 8) and a
0.05 significance level was used. Since none of the datasets used for statistical analysis, con-
tained sample sizes above six, no test for normality was included. Instead, the RT-qPCR data-
sets were analyzed for equal variances between the groups of each species (mono- compared to
co-culture) using an F-test. If the variances were insignificantly different, a parametric
unpaired t-test was used; while datasets that had significantly different variances were analyzed
using a non-parametric Mann-Whitney test. No statistical comparison was made across the
species, except for data sets regarding cell size, which were analyzed using two-way ANOVA
with Tukey’s multiple comparisons post hoc test to test the difference between mono- and co-
culturing within the same species and to analyze size difference between mBECs, rBECs, and
pBECs.
Results
Isolation of microvessels, cell growth, and in vitro BBB establishment
BECs were successfully isolated from mouse, rat, and porcine brains and used to construct
mono-cultures and co-cultures with both BECs and astrocytes isolated from the respective spe-
cies (Fig 1A and 1C). The mBECs exhibited slower cell growth than the rBECs and pBECs and
thus were cultured for an extra day before being re-seeded in the hanging culture inserts
(Fig 1A). mBECs were therefore isolated on day -4, while rBECs and pBECs were isolated on
day -3. The isolated microvessels are recognized as small pearls on a string, and after one day
(day -3 for mBECs and -2 for rBECs and pBECs) in culture the BECs start to proliferate from
the microvessels and grow into a monolayer reaching a confluence level of 80–90% on day 0
(Fig 1B). Astrocytes from each species were identified based on their expression of the glial
fibrillary acidic protein (GFAP) (Fig 1C).
Despite many similarities between the BECs derived from the three species, some differ-
ences do exist, especially in the number of cells obtained from one single isolation. For one
batch of mBECs, equal to 12 to -15 mice brains, enough cells for three 12 well plates with hang-
ing culture inserts (1.12cm2) are obtained. One batch of rBECs obtained from 9–12 rat brains
results in enough cells for six 12 well plates with hanging culture inserts, while 12 grams of
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porcine cortex is used for one batch of pBECs results in cells for seven 12 well plates with hang-
ing culture inserts (Fig 1A). We have tried to increase the output from the mBECs isolation by
increasing the number of mice brains to 18–20 brains; however, this did not result in a signifi-
cantly higher output of mBECs.
The BECs express tight junction proteins and form a tight barrier in vitro
In vivo, BECs are characterized by the expression of tight junction proteins restricting the
paracellular transport of solutes from the blood into the brain. Thus, we wanted to investigate
the gene expression of a subset of these tight junction proteins in the BECs cultured in mono-
culture and in co-culture with astrocytes, to investigate if co-culturing affected the expression
and whether differences in the gene expression pattern exits between the three species. When
comparing the effects of co-culturing the BECs with astrocytes on the expression of various
tight junction proteins, the expression pattern was somewhat similar across the three species
(Fig 2A). The expression of Cld1 decreased after co-culturing the BECs with astrocytes, and
the same tendency was observed when analyzing the expression of Zo2. However, despite mul-
tiple attempts with different primers and tissues reported with high expression of Zo2, the
expression of Zo2 in mBECs remained non-detectable (Fig 2A). The same applied to the analy-
sis of Cld3 in pBECs, which were non-detectable. The expression of both Cld3 and Cld5 by
mBECs and rBECs was unaffected by co-culturing, oppositely to the pBECs, which signifi-
cantly increased the expression of Cld5 after co-culturing (Fig 2A). Furthermore, the co-cul-
turing of BECs caused a significant increase in the expression of Zo1 (Fig 2A).
Next, we sought to confirm the protein expression of the major tight junction proteins
CLD5, OCLN, ZO-1, and ZO-2 and visualize their location in the BECs using immunocyto-
chemistry. The tight junction proteins are all expected to be located at the cell-cell junction
between two adjacent cells. In all three species, both the mono-cultured and co-cultured BECs
expressed CLD5, OCLN, and ZO-1 at the cell-cell junctions (Fig 2B). CLD5 staining was also
seen in the cytosol of mBECs and rBECs, probably due to the transport of the protein in vesi-
cles from the Golgi apparatus to the cell junctions. The expression of OCLN by mono-cultured
rBECs was weakly expressed at the cell-cell junctions, compared to the co-cultured rBECs,
which had a much more defined expression. In the mono-cultured rBECs and pBECs, OCLN
was primarily located in the cytosol and perinuclear region, indicating a high synthesis of the
protein, which was not seen in the co-cultures. This observation is consistent with the decrease
seen at the gene level at least in the co-cultured rBECs. Astrocytes might, therefore, have an
impact on the expression and location of OCLN. The gene expression of Zo2 was non-detect-
able in the mBECs (Fig 2A), and mono-cultured mBECs displayed negligent labeling of ZO-2,
however, co-culturing of the mBECs lead to a pronounced expression of ZO-2 at the cell-cell
junction (Fig 2B). Oppositely, to the mBECs, both rBECs and pBECs cultured in mono- and
co-culture displayed junctional expression of ZO-2 (Fig 2B). These results indicate that the
influence of astrocytes on the expression of tight junction proteins by BECs to some extend is
species-dependent. The protein levels of ZO-1 did not seem to be affected by the presence of
astrocytes: however, the organization of ZO-1 seemed to be affected, resulting in a clearer and
more organized localization at the cell-cell junction.
Correlation between transendothelial electrical resistance and permeability
The expression of tight junction proteins by the BECs contributes to the BECs having high
TEER and low permeability. Thus, the integrity of the in vitro BBB models was evaluated by
measuring TEER and analyzing the Papp of mannitol, a small molecule (182 Da) that is not a
ligand for any BECs transporters (Fig 3A and 3B). The addition of BBB induction factors on
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Fig 2. Expression of tight junction proteins. (A) Relative gene expression of claudin-1,-3,-5 (Cld1, Cld3, and Cld5), occludin (Ocln), and zonula occludens
1 and 2 (Zo1, Zo2) in mouse, rat, and porcine brain capillary endothelial cells (mBECs, rBECs, pBECs) cultured as mono-culture (black triangle) and as co-
culture with primary astrocytes (blue circle). The expression pattern of the different tight junction proteins is relatively similar across the three species. Co-
culturing the BECs with astrocytes decreases the expression of Cld1 and Zo2 compared to mono-cultured BECs. Oppositely, a significant increase in the
expression of Zo1 is seen after co-culturing the BECs. Cld3, Cld5, and Ocln are unaffected by the culturing conditions except when rBECs and pBECs are
co-cultured with astrocytes, where a significantly lower expression of Ocln or a significant increase in Cld5 expression is seen, respectively. Despite multiple
attempts, the expression of Cld3 and Zo2 is non-detectable in the pBECs and mBECs cultures, respectively. A change in gene expression between mono-
and co-cultures for each species is analyzed using an unpaired t-test or non-parametric Mann-Whitney test, depending on the variance of the data. Data are
shown as mean ± standard deviation (SD) (n = 6), �p< 0.05, ��p< 0.01, ���p< 0.001. (B) Immunofluorescent images showing green labeling at the cell-
cell borders of CLD5, OLCN, ZO-1, and ZO-2 in mBECs, rBECs, and pBECs cultured in mono- or co-culture with astrocytes. The BECs express CLD5,
OCLN, and ZO1 at the cell-cell interface independently of mono- or co-culturing. mBECs grown in mono-culture do not express ZO-2 at the cell borders,
however, a clear expression along the cell border is seen in co-cultured mBECs. Both rBECs and pBECs have a clear expression of ZO-2 along cell borders
independent of the culturing conditions. The nuclei are stained with DAPI (blue). Scale bar = 20μM.
https://doi.org/10.1371/journal.pone.0236770.g002
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day one caused a dramatic increase in the TEER (Fig 3A, day two), and co-culturing of the
BECs resulted in a further increase in TEER (Fig 3A). However, a large variation in TEER
exists from batch to batch but also when comparing the mBECs, rBECs, and pBECs. mBECs
reached maximum TEER on day three, where mean TEER values for mono-cultured mBECs
were 139.7 ± 15 Ω�cm2 and co-cultured mBECs 183.2 ± 46.3 Ω�cm2 (Fig 3A). rBECs reached
Fig 3. Evaluation of the blood-brain barrier integrity. (A) The transendothelial electrical resistance (TEER) (O�cm2) of mouse, rat, and porcine brain
capillary endothelial cells (mBECs, rBECs, pBECs) cultured in mono-culture (black triangles) and co-culture with astrocytes (blue circles). Co-culturing the
BECs with astrocytes causes an increase in TEER compared to mono-cultured BECs. Each triangle or circle represents an individual culture insert showing
a great variation in TEER across the inserts with identical culture conditions. Both mBECs and rBECs show a rapid increase in TEER after induction (day
1), peaking around day two to three, oppositely to pBECs, which have a slower increase in TEER peaking around day four. The data are illustrated as
mean ± standard deviation (SD) (mBECs n = 15, rBECs n = 10–11, and pBECs n = 15–18). (B) The functional barrier integrity of the BECs was additionally
evaluated by calculating the apparent permeability (Papp) of [3H]-D-Mannitol plotted against TEER across mBECs (black), rBECs (orange), and pBECs
(blue) cultured in mono-culture (triangles) or co-culture (circles). The higher the TEER, the lower the Papp; however, in the TEER range of 150–650O�cm2
only small differences in the Papp are observed. mBECs n = 12, rBECs n = 12, and pBECs n = 12–16 for each culturing condition. (C) Quantification of cell
area of mBECs, rBECs, and pBECs cultured in mono- and in co-culture. pBECs are significantly larger than both mBECs (p = ��) and rBECs (p = ���), and
co-culturing the BECs does not affect the cell size. The bottom panel shows representative images of how the area of the cells was quantified.
Scalebar = 20μM. To analyze the difference in size between mono- and co-cultured BECs within the same species and to compare differences in size
between species, a two-way ANOVA with Tukey’s multiple comparisons post hoc test was used. �� p< 0.01, ��� p< 0.001. Data are depicted as mean cell
area μm2 ± SD (n = 4).
https://doi.org/10.1371/journal.pone.0236770.g003
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maximum TEER on day two with mean TEER values of 167 ± 60.7 Ω�cm2 in mono-cultured
rBECs and 260.6 ± 105 Ω�cm2 for co-cultured rBECs. pBECs, on the other hand, had a slower
increase in TEER reaching its maximum on day four (Fig 3A). pBECs cultured in mono-cul-
ture displayed mean TEER values of 449.1 ± 178.4 Ω�cm2 and co-cultured pBECs reached
mean TEER values of 1182.3 ± 124.4 Ω�cm2.
As mentioned, the TEER values vary from batch to batch of isolated cells, thus all species
can reach both lower or higher TEER values than that displayed in Fig 3A, which visualizes
TEER values measured from individual filters of BECs from two different batches of isolated
cells. mBECs and rBECs normally display the highest TEER values for two days, during which
experiments are normally performed. After day three, the barrier integrity of mBECs and
rBECs decreases. pBECs, on the other hand, maintain a stable TEER for a longer period. In
this study, experiments on mBECs and rBECs were performed either on day two or three,
while experiments on pBECs were performed on day three or four. The pBECs reached signifi-
cantly higher TEER values than both of the rodent models, when comparing the different spe-
cies on the day of highest TEER within the same culture condition (P<0.001 for mono-
cultures, and co-cultures). No significant differences were found between the two rodent mod-
els (data not shown).
Besides TEER, the paracellular permeability was analyzed by measuring the Papp of [3H]-
mannitol (Fig 3B). The Papp of mannitol was measured in the mono- and co-cultured mBECs,
rBECs, and pBECs and plotted against TEER for each individual hanging culture insert. Since
the different species of BECs display different TEER ranges, an ongoing discussion regarding
choosing the most suitable in vitro BBB model for translational purposes is present both in the
literature and in the general BBB community, with some arguments that the rodent models,
displaying the lowest TEER values are leakier than the porcine and bovine models displaying
significantly higher TEER values. As already stated, we show that TEER values were signifi-
cantly higher in the in vitro BBB models established using pBECs compared to those estab-
lished with mBECs and rBECs. We, therefore, set out to investigate whether this meant that
mBECs and rBECs are more permeable than pBECs as indicated with lower TEER values. The
Papp data were therefore plotted in the same graph for comparison (Fig 3B). TEER values for
mBECs were in the range of 94 to 254 Ω�cm2, rBECs were in the range of 187 to 504 Ω�cm2,
and the TEER value range for pBECs was on the other hand much wider, ranging from 281 to
1509 Ω�cm2. In the lower TEER ranges (from 150–650 Ω�cm2) there is no clear correlation
between the permeability of [3H]-D-Mannitol and TEER. However, above 650 Ω�cm2 the per-
meability generally remains in the lower range. Looking at the data obtained from mBECs and
to some extend also the pBECs, TEER inversely correlated with the Papp of [3H]-D-Mannitol.
This pattern is, however, not seen in rBECs. All data points are within the range of 1.0�10−6 to
6.0�10−6 to (cm/s), which is within the normal range of that reported for in vitro BBB models
based on primary cells [7, 16]. Therefore, even though large differences are seen in TEER,
interestingly enough the permeability of [3H]-D-Mannitol is not highly variable between the
different species. mBECs, which show the lowest TEER range, still display Papp in the same
range as rBECs and pBECs, which both have higher TEER values. The Papp for pBECs in the
highest range (800–1500 Ω�cm2) is, however, generally lower than both mBECs and rBECs.
When looking at the immunocytochemical stainings of the mBECs, rBECs, and pBECs
(Fig 2B), it is clear that the size of the BECs varies. We, therefore, hypothesize that the differ-
ence seen in TEER values among the three species might be somewhat explained by different
sizes of the cells, with the argument that larger cells have fewer cell-cell junctions per filter
insert and therefore a smaller area for which flux of ions can occur, contributing to higher
TEER values. The area of the cells was, therefore, quantified by marking the cell-cell junctions
by immunolabeling the tight junctions of BECs cultured in mono- and co-culture with
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astrocytes (Fig 3C). The quantification of the cell area revealed that mBECs
(1,063.3 ± 222.7 μm2) were larger and had a larger variation in the size compared to the rBECs
(617.9 ± 135.8 μm2), while pBECs (1,773.4 ± 638.3 μm2) were significantly larger than both
mBECs and rBECs. Additionally, the pBECs displayed even larger variation in size with some
pBECs being roughly the same size as the mBECs and rBECs, while other pBECs were almost
three times as big. A phenomenon that was often seen in the pBEC cultures was multinuclear
cells, indicative of cell division. This was also sometimes seen in the mBEC cultures but rarely
in the rBEC cultures. No differences in size were observed between mono- and co-cultured
BECs within the same species. Representative images used for quantification of cell size are
shown in Fig 3C.
The BECs display functional efflux transporters independent of mono- or
co-culturing
In vivo, another important characteristic of the BECs is the presence of efflux transporters, as
these play an important role in protecting the brain from blood-borne lipophilic substances
that can passively diffuse across the cell membrane. Several different efflux transporters are
known, but the most studied are P-gp and BCRP. Therefore, we analyzed the gene expression
of Pgp and Bcrp in both mono- and co-cultured mBECs, rBECs, and pBECs (Fig 4A and 4B).
Pgp expression is significantly higher in mBECs upon co-culturing with astrocytes, while the
expression decreases significantly in rBECs when co-cultured. In pBECs, the expression is
unaffected by the culturing condition. The expression pattern of Bcrp in the BECs is on the
other hand highly similar among the different species showing significantly increased expres-
sion of Bcrp upon co-culturing (Fig 4C). The expression of P-gp was further confirmed on a
protein level by immunocytochemical staining (Fig 4C). P-pg was located in the cell cytoplasm
in all three species of BECs, but to some extend also at the cell-cell junction of pBECs, corre-
sponding well to previous reports [25]. Despite the differences observed in the gene expression
pattern of P-gp in the BECs (Fig 4A), no major differences were observed on a protein level
(Fig 4C).
To investigate the functionality and possible species differences of the P-gp efflux trans-
porter in the in vitro BBB models, the Papp in L-A and A-L of [3H]-digoxin, a P-gp substrate,
was measured with and without the influence of the P-gp inhibitor ZSQ. Both mono- and co-
cultured BECs had an active P-gp efflux transporter, as the difference between Papp L-A and
A-L diminished in the presence of ZSQ and no difference was observed between the different
species (Fig 4D–4F). The presence of an active efflux transporter in the BECs was further sup-
ported by calculating the ER based on the Papp data (Fig 4D–4F). The different BECs all had
ER >two and the ER decreased when adding ZQS inhibiting P-gp, confirming a polarized
active efflux transport of lipophilic molecules from the brain to the blood (Fig 4D) [48]. The
functionality of P-gp was unaffected by mono- or co-culturing of the BECs of different species
(Fig 4G).
Expression of TfR by BECs
Receptor-mediated transport across the BBB is one of the most studied mechanisms for active
transporting drugs across the BBB, and namely, the TfR has been extensively studied for
decades [43]. The expression of TfR was, therefore, investigated in mono- and mBECs, rBECs,
and pBECs co-cultured with astrocytes. The gene expression level of Tfr was unaffected by the
culturing condition with an identical expression pattern observed in all species (Fig 5A). The
expression of TfR was confirmed on the protein level using species-specific antibodies against
the mouse and the rat TfR. Unfortunately; we were unable to identify an antibody against the
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Fig 4. Expression and functionality of efflux transporters. (A+B) Relative gene expression of the efflux transporters P-glycoprotein
(Pgp) and breast cancer resistant protein (Bcrp) in mouse, rat, and porcine brain capillary endothelial cells (mBECs, rBECs, pBECs)
cultured in mono-culture (black triangle) and co-culture with astrocytes (blue circle). (A) The expression of Pgp increases significantly
in co-cultured mBECs, decreases significantly in co-cultured rBECs, but remains unchanged in pBECs. (B) The expression of Bcrp is
highly consistent in the BECs showing a significant increase in the expression upon co-culturing. (A+B) Changes in gene expression
between mono- and co-cultures for each species were analyzed using an unpaired t-test or non-parametric Mann-Whitney test,
depending on the variance of the data. Data are shown as mean ± standard deviation (SD) (n = 6), �p< 0.05, ��p< 0.01, ���p< 0.001.
(C) Immunofluorescent images showing green labeling of P-gp in the cell cytoplasm of BECs and also at the cell-cell borders in pBECs.
Staining patterns are unaffected by the culturing condition. The nuclei are stained with DAPI (blue). Scale bar = 20μM. (D-F) The
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porcine TfR that evoked reliable immunoreactivity. The TfR was primarily located in the cell
cytoplasm, which corresponds well with the intracellular trafficking of the TfR from the granu-
lar endoplasmic reticulum to the cellular surface and endosomal-lysosomal compartment [38,
39].
Discussion
In this study, we have constructed species-specific in vitro BBB models using primary BECs
isolated from mouse, rat, or porcine brains, and compared these in relation to several major
BEC characteristics, using the same protocol to isolate BECs from the three different species,
making the cells and models highly comparable. However, we observed a prominent difference
in the yield of BECs obtained per isolation, with the isolation of rBECs and pBECs giving a
much higher cellular output than the mBECs. The low yield of mBECs has also been reported
by other research groups [26, 49], suggesting that the feasibility and capacity of animal facili-
ties, should be taken into consideration when choosing an in vitro BBB model using mBECs.
Oppositely, the higher yield of rBECs and pBECs make these models cheaper and more
functionality of the efflux transporter P-gp was evaluated by measuring the apparent permeability (Papp) to [3H]-digoxin, a P-gp
substrate, with and without the P-gp inhibitor zosuquidar (ZSQ) in the luminal to abluminal (L-A) and abluminal to luminal (A-L)
direction. The difference between L-A and A-L transport, which is caused by an active P-gp efflux transporter, diminishes when P-gp is
inhibited. This applies to all three species independent of the culturing condition. Data are shown as mean ± SD (n = 6). (G) The efflux
ratio (ER) Papp(A-L)/Papp(L-A) calculated from Papp (D-F) shows ER above 2 for all species and culture conditions, which decreases
below 2 when P-gp is inhibited, indicative of an active polarized efflux transport function in the BECs. Data are shown as mean ± SD
(n = 2).
https://doi.org/10.1371/journal.pone.0236770.g004
Fig 5. Expression of the transferrin receptor (TfR). (A) Relative gene expression of Tfr, which is a highly targeted receptor at the BBB for drug delivery
purposes, in mouse, rat, and porcine brain capillary endothelial cells (mBECs, rBECs, pBECs) in mono-culture (black triangle) and co-culture with
astrocytes (blue circle). Tfr is expressed in all three species independent of the culturing conditions. Changes in gene expression between mono- and co-
cultures for each species were analyzed using an unpaired t-test or non-parametric Mann-Whitney test, depending on the variance of the data. No statistical
difference was found. Data are shown as mean ± standard deviation (SD) (n = 6). (B) Immunofluorescent images showing green labeling of the TfR in the
cell cytoplasm of both mBECs and rBECs, correspondingly well with the intracellular trafficking of the TfR. The nuclei are stained with DAPI (blue). Scale
bar = 20μM.
https://doi.org/10.1371/journal.pone.0236770.g005
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convenient to work with, with pBECs being the cheapest to isolate as most abattoirs have por-
cine brains as a by-product and might donate the porcine brains for research.
The expression pattern of various tight junction proteins
When comparing mono- and co-cultured BECs, it was evident that co-culturing the BECs
with astrocytes influenced the gene expression of many tight junction proteins. However, the
effect was not similar across mBECs, rBECs, and pBECs, suggesting differences in the com-
plexity by which the tight junction proteins are organized. As an example, Cld5 was upregu-
lated, and Zo2 downregulated in pBECs upon co-culturing, while these two proteins remained
unaffected in rBECs. In mBECs, Cld5 was likewise unaffected by co-culturing which is in good
accordance with the literature, showing that the expression of Cld5 is regulated by the addition
of BBB induction factors like RO, CTP-cAMP, and HC [28, 50, 51]. Zo2 was in our setup non-
detectable at the gene level in mBECs, probably due to low expression, which was confirmed
by ZO-2 immunolabeling showing negligent expression of ZO-2 in the mono-cultured
mBECs. This contradicts the findings by Stamatovic et. al., showing immunolabeling of ZO-2
in mono-cultured mBECs [52]. We were, however, able to see ZO-2 immunolabeling after co-
culturing, suggesting that in our setup mBECs expression and organization of ZO-2 are depen-
dent on the presence of astrocytes. We were unable to determine the Cld3 gene expression in
pBECs in our setup. However, CLD3 expression in pBECs has previously been confirmed by
immunolabeling [33], suggesting that this protein is also expressed by pBECs.
The difference in gene expression levels between mono- and co-cultured BECs or between
the species could not necessarily be translated to the protein level. The levels of protein did not
seem to increase or decrease as suggested by the gene expression analysis, however, instead,
the effect of co-culturing with astrocytes seemed to influence the organization and maturation
of the tight junction proteins. This corresponds well with the fact that both the integrity and
complexity of the tight junctions are increased after co-culturing with astrocytes [53, 54]. The
influence of astrocytes on the tight junction expression was most prominent in mBECs and
rBECs, and most obvious for the ZO-1 distribution at the cell-cell junctions. In mono-cultured
mBECs and rBECs, the organization of ZO-1 was irregular and did not completely close the
gap between the cell-cell junctions, while co-culturing the BECs resulted in the organization of
ZO-1 becoming more uniform without gaps between the cells, suggesting that the presence of
the astrocytes affected the maturation and organization of ZO-1 in the mBECs and rBECs. The
same phenomenon is to some degree also observed in pBECs, but not as obvious. The effect of
astrocytes on the expression of ZO-1 in BECs is probably through astrocytic secretion of sonic
hedgehoc, as downregulation of sonic hedgehoc in astrocytes causes downregulation of ZO-1
in BECs and a decreased barrier integrity [14]. The addition of the BBB induction factor
cAMP is also known to be able to increase the expression of tight junctions proteins [28, 54].
Furthermore, when comparing previously published immunolabelings of ZO-1 in rBECs cul-
tured in monolayers in well plates, without the presence of neither astrocytes nor tight junc-
tions inducing factors, the organization of ZO-1 seems to be highly affected by the addition of
the tight junction inducing factors [55], suggesting that cAMP and HC is also important for
the organization of this protein.
The distribution of OCLN was likewise affected by astrocytes, especially in the rBECs and
pBECs. Immunolabeling of OCLN in the mono-cultures was seen in the cytoplasm and peri-
nuclear areas indicating synthesis of OCLN, but when co-cultured, OCLN redistributed to the
cell-cell junctions. On a gene level, Ocln was downregulated in the rBECs, which suggests that
astrocytes affect the maturation and distribution of OCLN, by decreasing the synthesis and
increasing the organization of OCLN at the cell-cell junctions. The regulation of OCLN in
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BECs by astrocytes are also proposed to be through astrocytic secretion of sonic hedgehoc
[14], and that the influence of astrocytes is through the secretion of soluble factors supported
by several studies using astrocyte conditioned media, which is shown to be sufficient in induc-
ing BBB characteristics in BECs [34, 56]. Together these studies also support the use of non-
contact co-culture models, with astrocytes cultured in the bottom chamber, as used in the pres-
ent study.
Construction and integrity of the in vitro BBB models
The two types of in vitro BBB models used in this study were a simple mono-culture and the
non-contact co-culture model. Therefore, only the effect of the astrocytes on the different spe-
cies of BECs was investigated and compared, leaving the significance of pericytes for future
studies. The triple culture model has been referred to as the most in vivo like model, as this
model greatly mimics the anatomical structure of the BBB [29]. However, setting up the triple
culture model is complex, which is probably why this model is not commonly used, despite it
has been developed and characterized for all three species [22, 28, 29, 31, 57]. The mono-cul-
ture and the co-culture models are on the contrary easy to construct and therefore also the pre-
ferred models across different laboratories [32, 33, 37, 38, 40, 55, 58–61]. Future analysis of the
significance of pericytes in in vitro BBB models should include analysis of the vesicular trans-
port in the BECs as the presence of pericytes during embryogenesis decreases the vesicular
transport and contribute to the formation of tight junctions [10, 62]. Analysis of vesicular
transport has, therefore, not been included in the present study.
Oppositely to the small variations in the tight junction expression between mBECs, rBECs,
and pBECs large variations in the TEER range were observed. The co-cultured mBECs reached
TEER values around 150–250 Ω�cm2 while co-cultured rBECs reached values around 150–400
Ω�cm2 and co-cultured pBECs had TEER values between 500–1500 Ω�cm2. This is in good
accordance with the literature reporting similar TEER values for co-cultured mBECs, rBECs,
and pBECs [29, 58–60]. However, to obtain a functional assessment of the tightness of the bar-
riers, we wanted to further compare the TEER with the Papp of a small hydrophilic molecule
across the different models. Since the pBECs have the highest TEER values, we hypothesized
that pBECs would be less permeable, indicated by a lower Papp. We chose to investigate the
Papp of the small molecule mannitol (180 Da), as this is a widely used marker for evaluating
the functional tightness [7, 16, 25]. The Papp was in the range of 1–6�10−6 and as TEER
increased the Papp decreased in accordance with other studies [7, 16, 25]. However, in the
TEER range of 150–650 Ω�cm2, there was no clear correlation between permeability and
TEER, suggesting that mBEC cultures with a TEER of 200 Ω�cm2 are equally as impermeable
as pBEC culture with a TEER value of 650 Ω�cm2. Therefore, it cannot be postulated that
BECs from species reaching high TEER values are significantly more impermeable for small
hydrophilic molecules than BECs from species reaching lower TEER values at least when
TEER is below 650 Ω�cm2. This underlines the importance of TEER measurements being sup-
ported by permeability measurements. We propose that some of the differences in TEER and
Papp observed between mBECs, rBECs, and pBECs are caused by cell size differences, with the
pBECs being significantly larger than the mBECs and rBECs. Since pBECs are significantly
larger, the number of cells per hanging culture insert must be fewer, and thereby the cell-cell
junctions, through which molecules can pass, will be equally less. Additionally, since pigs
belong to the higher species compared to rodents, they might have a more complex organiza-
tion of tight junction proteins causing them to reach higher TEER values.
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Can in vitro BBB models be used for translational purposes?
An important characteristic of BECs in vivo is the expression of efflux transporters. We show
that our in vitro BBB models have polarized functional P-gp efflux transporters and that the
function is independent of mono- and co-culturing. The presence of functional P-gp efflux
transporters in in vitro models using primary BECs is also reported by other research groups
[29, 59, 63] and extensively reviewed in Helms et al; 2016 [7], supporting that our in vitro mod-
els are suitable for screening of small molecular drug transport and as all three species had a
polarized active P-gp transport, the choice of model can be independent of the species.
The TfR is the most studied target on the BBB for the delivery of bispecific antibodies and
nanoparticles [43]. We found equal gene expression of Tfr by mono- and co-cultured mBECs,
rBECs, and pBECs. However, positive immunolabeling of TfR was only reported for mBECs
and rBECs cultures. Monoclonal antibodies specific for the rodent TfR are known and widely
used both in vitro and in vivo. The OX26 antibody is highly specific against the rat TfR while
several specific monoclonal antibodies, e.g. the RI7217 antibody, have been developed to target
the mouse TfR [39, 41, 43, 64]. However, to our knowledge, no such monoclonal antibody tar-
geting the porcine TfR has been developed and used in drug delivery studies targeting the TfR
similar to those published for rats and mice. Only a few antibodies specifically developed
against the porcine TfR are commercially available, but since the porcine TfR might be some-
what similar to the human TfR, we also tested antibodies specific for the human TfR receptor
on the pBEC cultures. We were, however, unable to identify a satisfying TfR antibody that
labeled the porcine TfR receptor; for an overview of the tested antibodies, see Table 4. In vitro,
drug delivery studies targeting the TfR are mainly performed using the rodent in vitro BBB
models [39–41, 43]. The use of the in vitro BBB models based on mBECs and rBECs are pre-
ferred due to the high translatability to subsequent in vivo studies using both healthy and dis-
ease models.
Animal vs human in vitro BBB models
In the present study, the focus is on BBB models constructed with primary mouse, rat, and
porcine cells, since brain tissue from various animal sources is easy to obtain, and the cells
maintain many of the important BBB characteristics. However, human primary cells constitute
a theoretic optimal translational basis for a BBB model eliminating transgene hurdles, yet the
access to these cells is limited. The few models using primary human brain endothelial cells
(hBECs) are often obtained from biopsies from epilepsy-patients, thus impeding the founda-
tion of a normal BBB [65–67], or from commercial vendors, which only have limited informa-
tion on the source of the cells [7].
Primary hBECs generally express important BBB characteristics, like tight junction proteins
(OCLN, CLD5, and ZO-1), and functional efflux transporters [7, 65]. The yield of primary
hBECs has been reported to be 1�106 cells isolated from 5-10mm3 fresh brain tissue [65]. Oth-
ers have isolated from 4 to 7�106 cells from 1–13 grams of surgically removed fresh brain tis-
sue, and 2�106 to 2�107 cells from autopsy material [66]. We obtained approximately 4�106,
8�106, 9.4�106 cells per isolation respectively for mice, rat, and porcine brains, as stated earlier.
Therefore, the yield obtained from our animal models is higher compared to that obtained
from fresh human tissue, and without limited access. In many of the studies constructing in
vitro BBB models from primary hBECs, none or only the relative TEER values are provided
[65, 67]. However, a single study using mono-cultured primary hBECs reported TEER values
around 1000–1200 Ω�cm2 [67]. Looking at the immunocytochemical stains of the hBECs they
vary in size, with some being very large and others much smaller [65, 67], resembling what we
observed in the pBECs cultures. We found that the cell size might influence the TEER range,
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with larger cells, like pBECs, displaying higher TEER values, however, this is not necessarily
equal to a much lower permeability as shown for our pBECs models. Not surprisingly, based
on TEER and cell size primary hBECs are more similar to the pBECs than the mice and rBECs,
but as we have shown earlier in this study, this is not necessarily equal to the cells being supe-
rior to the rodent models with respect to the Papp of small molecules.
Moreover, in recent years stem cell technology has evolved enabling the creation of human
BBB models based on human pluripotent stem cells and human cord blood-derived stem cells
[68–71]. Both types of stem cell-based BBB models show promising BBB characteristics includ-
ing functional efflux transporters [68–71]. The models based on human pluripotent stem cells
show TEER values around 200–3000 Ω�cm2 for mono-cultures, around 1100 Ω�cm2 with
astrocyte conditioned media, and around 1450–3000 Ω�cm2 when co-cultured with rat astro-
cytes or human pericytes [68, 69, 71]. When the BBB phenotype is enhanced by the addition of
retinoic acid, the TEER values can be increased even further to approximately 5000 Ω�cm2
[72]. A Papp of 0.5–0.6�10−6 cm/s for sucrose has been reported for the human pluripotent
stem cell models, which are in the lowest range of all reported values obtained using in vitro
BBB models [7, 69, 71]. TEER values of only 70–160 Ω�cm2 depending on culture conditions
have been reported using hBECs derived from blood cord stem cells, with corresponding Papp
values of 10–20�10−6 cm/s for lucifer yellow, which is in the higher range but corresponds well
to the low TEER values [68–71]. Based on measures of integrity, the BBB models constructed
from hBECs derived from blood cord stem cells still need to be refined, whereas the BBB mod-
els constructed from hBECs derived from pluripotent stem cells seem highly promising. How-
ever, compared to the use of primary cells of animal origin, these models are very time-
consuming to establish, and the line-to-line and batch-to-batch variability in yield and cellular
phenotypes complicate the robustness of the process of differentiation from the human plurip-
otent stem cells [68, 70].
A few immortalized human BEC cell lines have been established, but often they lack crucial
BBB characteristics and are rarely fully characterized [73]. The immortalized human microvas-
cular endothelial cell line hCMEC/D3, established by Weksler et al in 2005 [74], remains one of
the most characterized and highly studied cell lines for the construction of a human in vitro
BBB model [7]. The hCMEC/D3 cell line expresses many of the important tight junction pro-
teins however, the expression of CLD5, OCLN, and JAM2 is low at both the gene and protein
levels [73, 75]. Especially the expression of CLD5 is critical for maintaining a low permeability
towards small molecules (<800 Da) [76], however, the low expression of the tight junction pro-
teins in these cells can be increased by optimizing the culture conditions, e.g. by the addition of
HC [74, 75, 77]. Depending on the culture conditions TEER values observed for hCMEC/D3
are normally in the range of 30–300 Ω�cm2 [13, 35, 73, 77], and permeability studies using
hCMEC/D3 reveal Papp for mannitol to be 24.7�10−6 cm/s [78]. This is 20 times higher than
the Papp reported in the present study, making all of our three animal models superior to the
hCMEC/D3 cell line concerning the Papp to mannitol. The low barrier integrity reported with
the hCMEC/D3 cell line might be due to the low expression of CLD5 in these cells, as men-
tioned previously [77]. It is well known that immortalized cell lines rarely reach TEER values
and low Papp values comparable to those obtained using primary cells, however, the hCMEC/
D3 express functional and polarized efflux transporters, like P-gp and BCRP, comparable to the
primary cells, making them useful for studying drug interactions at the BBB [73, 79].
Choosing the right in vitro model for future BBB modeling
The perfect in vitro BBB model would probably in most minds be of human origin, express all
the important BBB characteristics found in vivo, be low-cost, non-time consuming, easy to
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culture, and highly reproducible. However, at the moment, none of the human in vitro BBB
models can fulfill all of these criteria, why the use of animal in vitro BBB models is still justified,
as they display many characteristics of what would be considered an optimal model.
Current models all have advantages and disadvantages, why it is important to consider
these when planning future experiments. As stated previously, there has been an ongoing dis-
cussion regarding choosing the optimal in vitro BBB model solely based on TEER values, since
these vary significantly between different species. Instead, as also reported here, the Papp
should be taken into account as well since the differences in TEER might solely be due to size
differences between cells from rodents and higher animal species like the porcine. Instead one
should consider choosing a model that would add to the consistency between in vitro and in
vivo analysis. The in vitro BBB models constructed from mice would be more favorable to use
when planning to move forward with in vivo studies using e.g. transgenic mice models. When
studying potential drug interaction with the efflux transporters before moving into human
clinical trials, it makes perfect sense to choose among the human in vitro BBB models, despite
these do not express the necessary characteristic for sufficient barrier integrity. Likewise, when
targeting the TfR for drug delivery across the BBB, it might be favorable to use one of the
rodent models, since well-characterized antibodies have been developed against the TfR in
these models. Despite the high output of cells and the easy and cheap access to porcine brain
tissue, some gene and protein analyses are still highly challenged. Therefore, as no model
seems superior to the others, the choice of in vitro BBB model should primarily be based on
the purpose of the study, rather than a wish to obtain the highest TEER values.
Conclusion
Based on the results from the present study, we conclude that not many differences exist when
comparing mBECs, rBECs, and pBECs. However, the yield and translatability from in vitro to
in vivo studies are parameters to consider. pBECs would be easy and cheap to use for high
throughput in vitro drug delivery studies due to low costs and high cell yield, as opposed to
mBECs. Isolation of mBECs result is the lowest cellular yield, but many in vivo disease mouse
models exist enabling translation to in vivo research. This is opposed to the pBECs, which
results in a high yield of cells but the translation to in vivo transgenic pig models is much more
complicated. The use of pBECs is also complicated due to e.g. the availability of specific anti-
bodies targeting porcine proteins. Furthermore, we find that the significantly higher TEER
measurements obtained with the porcine in vitro BBB model are not necessarily translatable to
a much less permeable cell layer compared to in vitro BBB models of mice or rat origin, as the
Papp of [3H]-D-Mannitol is low for all three models. The large variation in TEER could
instead be due to a significantly larger cell size of the pBECs compared to the mBEC3s and
rBECs or be explained by a more complex organization of tight junction proteins in pBECs
causing them to reach significantly higher TEER values. Finally, co-culturing BECs with astro-
cytes is preferable to maintain as many in vivo characteristics as possible and highly affect the
gene expression pattern of the tight junction proteins. As stated earlier, the choice of in vitro
BBB model should be based on the aim of application rather than false assumptions of high
TEER being equal to a superior model.
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